8-K
AVANOS MEDICAL, INC. (AVNS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: November 1, 2023
(Date of earliest event reported)
Commission file number 001-36440
AVANOS MEDICAL, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 46-4987888 | |||
|---|---|---|---|---|
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||
| 5405 Windward Parkway | ||||
| Suite 100 South | ||||
| Alpharetta, | Georgia | 30004 | ||
| (Address of principal executive offices) | (Zip code) |
Registrant’s telephone number, including area code: (844) 428-2667
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered |
|---|---|---|
| Common Stock - $0.01 Par Value | AVNS | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
Avanos Medical, Inc. (the “Company”) announced its results of operations for the three and nine months ended September 30, 2023 in a press release dated November 1, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.
The information contained in Item 2.02 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information in Item 2.02 of this Current Report or Exhibit 99.1 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Item 9.01 Financial Statements and Exhibits
(d)Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release issued by Avanos Medical, Inc. onNovember 1, 2023 |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AVANOS MEDICAL, INC. | |||
|---|---|---|---|
| Date: | November 1, 2023 | By: | /s/ Mojirade James |
| Mojirade James<br>Senior Vice President and General Counsel |
Document
| Investor Contact: Michael Greiner |
|---|
| Avanos Medical, Inc. |
| 470-562-2692 |
| Investor.Relations@Avanos.com |
| Media Contact: Katrine Kubis |
| Avanos Medical, Inc. |
| CorporateCommunications@Avanos.com |
Avanos Medical, Inc. Announces Third Quarter 2023 Results
Strong Free Cash Flow Generation in Excess of $25 Million
ALPHARETTA, Ga., November 1, 2023/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2023 financial results.
“We are pleased with our results for this quarter as we continue to deliver above-market growth in our Digestive Health markets,” said Joe Woody, Avanos’s chief executive officer. Woody continued, “We believe we are poised to sustain the momentum in Digestive Health and we are also confident that our strategy for the Pain Management and Recovery business will lead to sustainable growth as we enter 2024.”
Third Quarter 2023 Financial Highlights
•Total net sales from continuing operations were $171.3 million, a 0.6% decrease from the comparable prior year period.
•Net loss from continuing operations for the quarter was $8.8 million, compared to net income from continuing operations of $11.0 million a year ago.
•Adjusted net income from continuing operations totaled $14.0 million, compared to $11.5 million a year ago.
•Diluted loss per share from continuing operations was $0.19, compared to diluted earnings per share of $0.23 a year ago.
•Adjusted diluted earnings per share from continuing operations was $0.30, compared to $0.24 a year ago.
Operational and Business Highlights
On October 2, we completed the sale of substantially all of the assets primarily related to or used in our RH business (the “Divestiture”). The Divestiture represents a key component of our ongoing transformation process and is aimed at accelerating our effort to focus our portfolio in markets where we believe we are well-positioned to succeed.
On July 24, we closed the acquisition of Diros Technology, Inc. (“Diros”). Based in Toronto, Canada, Diros is at the forefront of radiofrequency ablation (“RFA”) technology. The addition of Diros’ unique RF TridentTM technology is expected to further enhance Avanos’ Pain Management and Recovery treatment options and complement our premium COOLIEF* Cooled Radiofrequency product offering.
The Divestiture and the acquisition of Diros is part of our three-year transformation initiative that we announced early this year. This initiative is focused on four key priorities: optimizing our commercial organization; transforming our product portfolio; implementing cost management initiatives to enhance operating profitability; and continuing to efficiently deploy capital while maintaining a focused and disciplined approach to M&A (the “Transformation
Process”). We anticipate that by 2025, this plan will ultimately result in savings of between $45 million and $55 million compared to 2022.
Third Quarter 2023 Operating Results From Continuing Operations
For the three months ended September 30, 2023, net sales totaled $171.3 million, a decrease of 0.6% compared to the prior year period, primarily from lower HA sales, partially offset by higher volume in the Digestive Health portfolio and slightly favorable pricing and foreign currency translation effects.
As a result of the Divestiture, the RH business’s operating results are reflected as discontinued operations for all periods presented. Treating the RH business as discontinued operations results in significant shared overhead costs previously allocated to the RH business that are now included in continuing operations. Included in continuing operations are costs previously allocated to the RH business of $10.3 million in the three months ended September 30, 2023 compared to $8.3 million in the three months ended September 30, 2022.
Gross margin during the third quarter of 2023 was 55.8%, compared to 58.2% in the prior year period. Adjusted gross margin was 58.2% compared to 60.3% last year. Gross profit margin decreased primarily due to product mix, partially offset by slightly favorable currency exchange rates and manufacturing efficiencies.
Selling and general expenses as a percentage of net sales was 45.9% for the third quarter of 2023, compared to 45.4% for the third quarter of 2022 primarily due to non-recurring expenses associated with our ongoing Transformation Process and the Divestiture.
Operating profit was $1.2 million, compared to $12.8 million in the prior year period, primarily due to overall lower sales volume along with an increase in expenses related to the Transformation Process and the Divestiture. On an adjusted basis, operating profit totaled $23.0 million, compared to $20.7 million a year ago.
Adjusted EBITDA from continuing operations was $27.8 million in the three months ended September 30, 2023, compared to $25.2 million in the three months ended September 30, 2022.
First Nine Months 2023 Operating Results From Continuing Operations
For the nine months ended September 30, 2023, net sales totaled $500.0 million, a decrease of 0.5% compared to the prior year period, primarily due to lower volume in the Pain Management and Recovery portfolio (primarily lower HA sales), partially offset by continued strong demand for Digestive Health products. Favorable pricing was mostly offset by unfavorable foreign currency translation effects.
Gross margin for the nine months ended September 30, 2023 was 56.9%, compared to 58.0% in the prior year period. Adjusted gross margin was 59.2% compared to 60.3% last year. Gross margin decreased primarily due to product mix partially offset by manufacturing efficiencies.
Selling and general expenses as a percentage of net sales was 52.1% for the nine months ended September 30, 2023, compared to 49.3% for the prior year period, primarily due to non-recurring expenses associated with our ongoing Transformation Process and the Divestiture.
Operating loss for the nine months ended September 30, 2023 was $7.0 million, compared to operating income of $18.9 million in the prior year period, primarily due to overall lower sales volume along with an increase in expenses related to the Transformation Process and the Divestiture. On an adjusted basis, operating profit totaled $52.6 million, compared to $43.7 million a year ago.
Shared overhead costs previously allocated to the RH business were $34.5 million in the nine months ended September 30, 2023 compared to $33.3 million in the prior year period.
Adjusted EBITDA from continuing operations for the nine months ended September 30, 2023 was $66.8 million, compared to $57.0 million in the prior year period.
Cash Flow and Balance Sheet
Cash from operations less capital expenditures, or free cash flow, for the third quarter was $25.2 million, driven primarily by cash generated by operating activities, compared to $23.1 million a year ago. The Company’s cash balance at September 30, 2023 was $107.1 million, compared to $127.7 million at year-end 2022.
Total debt outstanding, net of unamortized discounts, was $264.5 million at September 30, 2023, compared to $232.5 million at December 31, 2022. Today our total debt outstanding is $169 million and cash and equivalents on hand is $105 million.
Discontinued Operations
Net sales from discontinued operations were $31.1 million and $93.9 million in the three and nine months ended September 30, 2023, respectively, compared to $29.8 million and $100.0 million in the three and nine months ended September 30, 2022, respectively. We expect a loss on the disposal of the RH business; accordingly, we recorded an impairment of $72.3 million against assets in the disposal group, which is included in “(Loss) income from discontinued operations, net of tax.”
2023 Outlook
For the year, the Company anticipates revenue between $675 million and $685 million from continuing operations, adjusted gross margins greater than 59% and adjusted diluted earnings per share from continuing operations of between $1.05 and $1.15 for the year.
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
•Adjusted net income
•Adjusted diluted earnings per share
•Adjusted gross and operating profit
•Adjusted effective tax rate
•Adjusted EBITDA
•Free cash flow
These non-GAAP financial measures exclude the following items, as applicable, for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
•Certain acquisition and integration charges related to acquisitions.
•Expenses associated with restructuring and transformation activities, including the Divestiture.
•Expenses associated with European Union Medical Device Regulation (“EU MDR”) compliance.
•The amortization of intangible assets associated with prior business acquisitions.
•The tax effects of certain adjusting items.
•The benefit associated with the tax effects of the CARES Act.
•The positive or negative effect of changes in currency exchange rates during the year.
The Company provides these non-GAAP financial measures as supplemental information to its GAAP financial measures. Management and the Company’s board of directors use net sales on a constant currency basis, adjusted net income, adjusted diluted earnings per share, adjusted operating profit, adjusted EBITDA, and free cash flow to: (a) evaluate the Company’s historical and prospective financial performance and its performance relative to its competitors,
(b) allocate resources and (c) measure the operational performance of the Company’s business units and their managers. Management also believes that the use of an adjusted effective tax rate provides improved insight into the tax effects of the Company’s ongoing business operations.
Additionally, the compensation committee of the Company’s board of directors will use certain of the non-GAAP financial measures when setting and assessing achievement of incentive compensation goals. These goals are based, in part, on the Company’s net sales on a constant currency basis and adjusted EBITDA, which will be determined by excluding certain items that are used in calculating these non-GAAP financial measures.
Our competitors may define these non-GAAP financial measures differently, and as a result, our measure of these non-GAAP financial measures may not be directly comparable to those of other companies. Items excluded from these non-GAAP financial measures are significant components in understanding and assessing financial performance. These non-GAAP financial measures are supplemental measures of operating performance that do not represent, and should not be considered in isolation or as an alternative to, or substitute for, the financial statement data presented in the Company’s consolidated financial statements as indicators of financial performance. These non-GAAP financial measures have limitations as analytical tools, and should not be considered in isolation, or as a substitute for analysis of the Company’s results as reported under GAAP. We compensate for these limitations by relying primarily on our GAAP results and using these non-GAAP financial measures as supplemental information.
Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the attached financial tables.
Conference Call Webcast
Avanos Medical, Inc. will host a conference call today at 9 a.m. ET. The conference call can be accessed live over the internet at https://avanos.investorroom.com or via telephone by dialing 877-240-5772 in the United States. A replay of the call will be available at noon ET today by calling 877-344-7529 in the United States and entering passcode 9384291. A webcast of the call will also be archived in the Investors section on the Avanos website.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today’s most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio. For more information, visit www.avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.
Forward-Looking Statements
This press release contains information that includes or is based on “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the current plans and expectations of management and are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by the use of words such as “may,” “believe,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan” or “continue” and similar expressions. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; shortage in drugs used in our Surgical Pain and Recovery products or other disruptions in our supply chain; the ongoing regional conflicts between Russia and Ukraine and in the Middle East; our ability to successfully execute on or achieve the expected benefits of the Transformation Process or our divestiture, acquisition or merger transactions; inflationary pressures; the effects of the recent financial conditions affecting the banking system and the potential threats to the solvency of commercial banks; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the impact of investigative and legal proceedings and compliance risks;
the impact of the federal legislation to reform the United States healthcare system; changes in financial markets; and changes in the competitive environment. The information contained herein speaks only as of the date of this release and we undertake no obligation to update forward-looking statements, except as may be required by the securities laws.
Additional information concerning these and other factors that may impact future results is contained in our filings with the U.S. Securities and Exchange Commission, including our most recent Form 10-Q.
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED INCOME STATEMENTS
(unaudited)
(in millions, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |||||
| Net Sales | $ | 171.3 | $ | 172.3 | $ | 500.0 | $ | 502.5 |
| Cost of products sold | 75.8 | 72.1 | 215.3 | 211.2 | ||||
| Gross Profit | 95.5 | 100.2 | 284.7 | 291.3 | ||||
| Research and development expenses | 6.1 | 7.1 | 20.4 | 22.0 | ||||
| Selling and general expenses | 78.7 | 78.3 | 260.5 | 247.8 | ||||
| Other expense, net | 9.5 | 2.0 | 10.8 | 2.6 | ||||
| Operating Income (Loss) | 1.2 | 12.8 | (7.0) | 18.9 | ||||
| Interest income | 0.9 | 0.3 | 1.9 | 0.5 | ||||
| Interest expense | (4.7) | (3.0) | (11.7) | (7.0) | ||||
| (Loss) Income Before Income Taxes | (2.6) | 10.1 | (16.8) | 12.4 | ||||
| Income tax (provision) benefit | (6.2) | 0.9 | (4.1) | (0.6) | ||||
| (Loss) Income from Continuing Operations | (8.8) | 11.0 | (20.9) | 11.8 | ||||
| Income (Loss) from discontinued operations, net of tax | 5.1 | 4.7 | (51.4) | 21.8 | ||||
| Net (Loss) Income | $ | (3.7) | $ | 15.7 | $ | (72.3) | $ | 33.6 |
| Interest expense, net | $ | 3.8 | $ | 2.7 | $ | 9.8 | $ | 6.5 |
| Income tax benefit | 7.8 | 0.3 | 6.3 | 7.7 | ||||
| Depreciation and amortization | 11.0 | 11.6 | 34.6 | 34.3 | ||||
| EBITDA | $ | 18.9 | $ | 30.3 | $ | (21.6) | $ | 82.1 |
| (Loss) Earnings Per Share | ||||||||
| Basic | ||||||||
| Continuing operations | $ | (0.19) | $ | 0.24 | $ | (0.45) | $ | 0.25 |
| Discontinued operations | 0.11 | 0.10 | (1.10) | 0.46 | ||||
| Basic (Loss) Earnings Per Share | $ | (0.08) | $ | 0.34 | $ | (1.55) | $ | 0.71 |
| Diluted | ||||||||
| Continuing operations | $ | (0.19) | $ | 0.23 | $ | (0.45) | $ | 0.25 |
| Discontinued operations | $ | 0.11 | 0.10 | (1.10) | 0.46 | |||
| Diluted (Loss) Earnings Per Share | $ | (0.08) | $ | 0.33 | $ | (1.55) | $ | 0.71 |
| Common Shares Outstanding | ||||||||
| Basic | 46.8 | 46.6 | 46.7 | 47.1 | ||||
| Diluted | 46.8 | 47.0 | 46.7 | 47.5 |
AVANOS MEDICAL, INC.
Discontinued Operations Summary
(unaudited)
(in millions, except per share amounts)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |||||
| Net Sales | $ | 31.1 | $ | 29.8 | $ | 93.9 | $ | 100.0 |
| Cost of products sold | 19.9 | 19.9 | 57.8 | 58.2 | ||||
| Gross Profit | 11.2 | 9.9 | 36.1 | 41.8 | ||||
| Research and development expenses | 0.2 | 0.2 | 0.8 | 1.1 | ||||
| Selling, general and other expenses | 4.2 | 3.8 | 11.9 | 11.5 | ||||
| Other expense, net | 0.1 | — | 0.3 | 0.3 | ||||
| Operating Income | 6.7 | 5.9 | 23.1 | 28.9 | ||||
| Pretax loss on classification as discontinued operations | — | — | (72.3) | — | ||||
| Income (Loss) from discontinued operations before income taxes | 6.7 | 5.9 | (49.2) | 28.9 | ||||
| Income tax provision from discontinued operations | (1.6) | (1.2) | (2.2) | (7.1) | ||||
| Income (Loss) from discontinued operations, net of tax | $ | 5.1 | $ | 4.7 | $ | (51.4) | $ | 21.8 |
| Earnings (Loss) Per Share | ||||||||
| Basic | $ | 0.11 | $ | 0.10 | $ | (1.10) | $ | 0.46 |
| Diluted | $ | 0.11 | $ | 0.10 | $ | (1.10) | $ | 0.46 |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| Gross Profit | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | 95.5 | $ | 11.2 | $ | 106.7 | $ | 100.2 | $ | 9.9 | $ | 110.1 | ||||||
| Restructuring and transformation charges | 0.6 | — | 0.6 | — | — | — | ||||||||||||
| EU MDR Compliance | — | — | — | 0.2 | — | 0.2 | ||||||||||||
| Intangibles amortization | 3.6 | — | 3.6 | 3.5 | — | 3.5 | ||||||||||||
| As adjusted non-GAAP | $ | 99.7 | $ | 11.2 | $ | 110.9 | $ | 103.9 | $ | 9.9 | $ | 113.8 | ||||||
| Gross profit margin, as reported | 55.8 | % | 36.0 | % | 52.7 | % | 58.2 | % | 33.2 | % | 54.5 | % | ||||||
| Gross profit margin, as adjusted | 58.2 | % | 36.0 | % | 54.8 | % | 60.3 | % | 33.2 | % | 56.3 | % | ||||||
| Gross Profit | ||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | 284.7 | $ | 36.1 | $ | 320.8 | $ | 291.3 | $ | 41.8 | $ | 333.1 | ||||||
| Acquisition and integration-related charges | — | — | — | 1.4 | — | 1.4 | ||||||||||||
| Restructuring and transformation charges | 0.6 | — | 0.6 | — | — | — | ||||||||||||
| EU MDR Compliance | — | — | — | 0.2 | — | 0.2 | ||||||||||||
| Intangibles amortization | 10.8 | — | 10.8 | 10.1 | — | 10.1 | ||||||||||||
| As adjusted non-GAAP | $ | 296.1 | $ | 36.1 | $ | 332.2 | $ | 303.0 | $ | 41.8 | $ | 344.8 | ||||||
| Gross profit margin, as reported | 56.9 | % | 38.4 | % | 54.0 | % | 58.0 | % | 41.8 | % | 55.3 | % | ||||||
| Gross profit margin, as adjusted | 59.2 | % | 38.4 | % | 55.9 | % | 60.3 | % | 41.8 | % | 57.2 | % |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| Operating Profit | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | 1.2 | $ | 6.7 | $ | 7.9 | $ | 12.8 | $ | 5.9 | $ | 18.7 |
| Acquisition and integration-related charges | 0.6 | — | 0.6 | 0.2 | — | 0.2 | ||||||
| Restructuring and transformation charges(a) | 4.3 | — | 4.3 | — | — | — | ||||||
| Divestiture related charges | 1.4 | 0.8 | 2.2 | — | — | — | ||||||
| EU MDR Compliance(b) | 0.8 | — | 0.8 | 2.2 | — | 2.2 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 6.2 | — | 6.2 | 5.5 | 0.6 | 6.1 | ||||||
| As adjusted non-GAAP | $ | 23.0 | $ | 7.5 | $ | 30.5 | $ | 20.7 | $ | 6.5 | $ | 27.2 |
| Operating (Loss) Profit | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | (7.0) | $ | 23.1 | $ | 16.1 | $ | 18.9 | $ | 28.9 | $ | 47.8 |
| Acquisition and integration-related charges | 2.4 | — | 2.4 | 3.0 | — | 3.0 | ||||||
| Restructuring and transformation charges(a) | 23.0 | — | 23.0 | — | — | — | ||||||
| Divestiture related charges | 5.1 | 0.8 | 5.9 | — | — | — | ||||||
| EU MDR Compliance(b) | 2.8 | — | 2.8 | 5.4 | — | 5.4 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 17.8 | 0.8 | 18.6 | 16.4 | 1.6 | 18.0 | ||||||
| As adjusted non-GAAP | $ | 52.6 | $ | 24.7 | $ | 77.3 | $ | 43.7 | $ | 30.5 | $ | 74.2 |
__________________________________________________
(a) Expenses incurred for the Transformation Process are included in “Costs of products sold,” “Research and development,” “Selling and general expenses” and “Other expense, net” on the Condensed Consolidated Income Statements.
(b) In the three and nine months ended September 30, 2023, EU MDR Compliance related charges are included in “Selling and general expenses” on the Condensed Consolidated Income Statements. In the three and nine months ended September 30, 2022, EU MDR Compliance related charges are included in “Costs of products sold” and “Selling and general expenses” on the Condensed Consolidated Income Statements.
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| (Loss) Income Before Taxes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | (2.6) | $ | 6.7 | $ | 4.1 | $ | 10.1 | $ | 5.9 | $ | 16.0 |
| Acquisition and integration-related charges | 0.6 | — | 0.6 | 0.2 | — | 0.2 | ||||||
| Restructuring and transformation charges | 4.3 | — | 4.3 | — | — | — | ||||||
| Divestiture related charges | 1.4 | 0.8 | 2.2 | — | — | — | ||||||
| EU MDR Compliance | 0.8 | — | 0.8 | 2.2 | — | 2.2 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 6.2 | — | 6.2 | 5.5 | 0.6 | 6.1 | ||||||
| As adjusted non-GAAP | $ | 19.2 | $ | 7.5 | $ | 26.7 | $ | 18.0 | $ | 6.5 | $ | 24.5 |
| (Loss) Income Before Taxes | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | (16.8) | $ | (49.2) | $ | (66.0) | $ | 12.4 | $ | 28.9 | $ | 41.3 |
| Acquisition and integration-related charges | 2.4 | — | 2.4 | 3.0 | — | 3.0 | ||||||
| Restructuring and transformation charges | 23.0 | — | 23.0 | — | — | — | ||||||
| Divestiture related charges | 5.1 | 0.8 | 5.9 | — | — | — | ||||||
| Estimated loss on Divestiture | — | 72.3 | 72.3 | — | — | — | ||||||
| EU MDR Compliance | 2.8 | — | 2.8 | 5.4 | — | 5.4 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 17.8 | 0.8 | 18.6 | 16.4 | 1.6 | 18.0 | ||||||
| Loss on extinguishment of debt | — | — | — | 1.1 | — | 1.1 | ||||||
| As adjusted non-GAAP | $ | 42.8 | $ | 24.7 | $ | 67.5 | $ | 38.3 | $ | 30.5 | $ | 68.8 |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| Tax (Provision) Benefit | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | (6.2) | $ | (1.6) | $ | (7.8) | $ | 0.9 | $ | (1.2) | $ | (0.3) | ||||||
| Tax effects of adjusting items | 1.0 | (0.4) | 0.6 | (3.6) | 1.1 | (2.5) | ||||||||||||
| Effects of the CARES Act and other(a) | — | — | — | (3.8) | — | (3.8) | ||||||||||||
| As adjusted non-GAAP | $ | (5.2) | $ | (2.0) | $ | (7.2) | $ | (6.5) | $ | (0.1) | $ | (6.6) | ||||||
| Effective tax rate, as reported | 238.5 | % | 23.9 | % | 190.2 | % | 8.9 | % | 20.3 | % | 1.9 | % | ||||||
| Effective tax rate, as adjusted | 27.0 | % | 26.7 | % | 26.9 | % | 36.1 | % | 1.5 | % | 26.9 | % | ||||||
| Tax (Provision) | ||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | (4.1) | $ | (2.2) | $ | (6.3) | $ | (0.6) | $ | (7.1) | $ | (7.7) | ||||||
| Tax effects of adjusting items | (7.5) | (4.4) | (11.9) | (7.6) | 0.5 | (7.1) | ||||||||||||
| Effects of the CARES Act and other(a) | — | — | — | (3.8) | — | (3.8) | ||||||||||||
| As adjusted non-GAAP | $ | (11.6) | $ | (6.6) | $ | (18.2) | $ | (12.0) | $ | (6.6) | $ | (18.6) | ||||||
| Effective tax rate, as reported | 24.4 | % | 4.5 | % | 9.5 | % | 4.8 | % | 24.6 | % | 18.6 | % | ||||||
| Effective tax rate, as adjusted | 27.0 | % | 26.7 | % | 26.9 | % | 31.3 | % | 21.7 | % | 27.1 | % |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)
| Net (Loss) Income | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | (8.8) | $ | 5.1 | $ | (3.7) | $ | 11.0 | $ | 4.7 | $ | 15.7 |
| Acquisition and integration-related charges | 0.6 | — | 0.6 | 0.2 | — | 0.2 | ||||||
| Restructuring and transformation charges | 4.3 | — | 4.3 | — | — | — | ||||||
| Divestiture related charges | 1.4 | 0.8 | 2.2 | — | — | — | ||||||
| EU MDR Compliance | 0.8 | — | 0.8 | 2.2 | — | 2.2 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 6.2 | — | 6.2 | 5.5 | 0.6 | 6.1 | ||||||
| Tax effects of adjusting items | 1.0 | (0.4) | 0.6 | (3.6) | 1.1 | (2.5) | ||||||
| Tax effects of the CARES Act and other | — | — | — | (3.8) | — | (3.8) | ||||||
| As adjusted non-GAAP | $ | 14.0 | $ | 5.5 | $ | 19.5 | $ | 11.5 | $ | 6.4 | $ | 17.9 |
| Diluted (loss) earnings per share, as reported | $ | (0.19) | $ | 0.11 | $ | (0.08) | $ | 0.23 | $ | 0.10 | $ | 0.33 |
| Diluted earnings per share, as adjusted | $ | 0.30 | $ | 0.12 | $ | 0.42 | $ | 0.24 | $ | 0.14 | $ | 0.38 |
| Net (Loss) Income | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| As reported | $ | (20.9) | $ | (51.4) | $ | (72.3) | $ | 11.8 | $ | 21.8 | $ | 33.6 |
| Acquisition and integration-related charges | 2.4 | — | 2.4 | 3.0 | — | 3.0 | ||||||
| Restructuring and transformation charges | 23.0 | — | 23.0 | — | — | — | ||||||
| Divestiture related charges | 5.1 | 0.8 | 5.9 | — | — | — | ||||||
| Estimated loss on divestiture | — | 72.3 | 72.3 | — | — | — | ||||||
| EU MDR Compliance | 2.8 | — | 2.8 | 5.4 | — | 5.4 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Intangibles amortization | 17.8 | 0.8 | 18.6 | 16.4 | 1.6 | 18.0 | ||||||
| Loss on extinguishment of debt | — | — | — | 1.1 | — | 1.1 | ||||||
| Tax effects of adjusting items | (7.5) | (4.4) | (11.9) | (7.6) | 0.5 | (7.1) | ||||||
| Tax effects of the CARES Act and other | — | — | — | (3.8) | — | (3.8) | ||||||
| As adjusted non-GAAP | $ | 31.2 | $ | 18.1 | $ | 49.3 | $ | 26.3 | $ | 23.9 | $ | 50.2 |
| Diluted (loss) earnings per share, as reported | $ | (0.45) | $ | (1.10) | $ | (1.55) | $ | 0.25 | $ | 0.46 | $ | 0.71 |
| Diluted earnings per share, as adjusted | $ | 0.67 | $ | 0.39 | $ | 1.06 | $ | 0.55 | $ | 0.50 | $ | 1.05 |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)
| Selling, General and Administrative Expenses | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | 78.7 | $ | 4.2 | $ | 82.9 | $ | 78.3 | $ | 3.8 | $ | 82.1 | ||||||
| Acquisition and integration-related charges | (0.6) | — | (0.6) | (0.2) | — | (0.2) | ||||||||||||
| Restructuring and transformation charges(a) | (2.1) | — | (2.1) | — | — | — | ||||||||||||
| Divestiture related charges | (1.4) | (0.8) | (2.2) | — | — | — | ||||||||||||
| EU MDR Compliance (b) | (0.8) | — | (0.8) | (1.9) | — | (1.9) | ||||||||||||
| Intangibles amortization | (2.6) | — | (2.6) | (2.1) | (0.6) | (2.7) | ||||||||||||
| As adjusted non-GAAP | $ | 71.2 | $ | 3.4 | $ | 74.6 | $ | 74.1 | $ | 3.2 | $ | 77.3 | ||||||
| SG&A as a percentage of revenue, as reported | 45.9 | % | 13.5 | % | 41.0 | % | 45.4 | % | 12.8 | % | 40.6 | % | ||||||
| SG&A as a percentage of revenue, as adjusted | 41.6 | % | 10.9 | % | 36.9 | % | 43.0 | % | 10.7 | % | 38.2 | % | ||||||
| Selling, General and Administrative Expenses | ||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||||||||
| As reported | $ | 260.5 | $ | 11.9 | $ | 272.4 | $ | 247.8 | $ | 11.5 | $ | 259.3 | ||||||
| Acquisition and integration-related charges | (1.0) | — | (1.0) | (1.6) | — | (1.6) | ||||||||||||
| Restructuring and transformation charges(a) | (20.5) | — | (20.5) | — | — | — | ||||||||||||
| Divestiture related charges | (5.1) | (0.8) | (5.9) | — | — | — | ||||||||||||
| EU MDR Compliance (b) | (2.8) | — | (2.8) | (5.2) | — | (5.2) | ||||||||||||
| Intangibles amortization | (7.0) | (0.8) | (7.8) | (6.4) | (1.5) | (7.9) | ||||||||||||
| As adjusted non-GAAP | $ | 224.1 | $ | 10.3 | $ | 234.4 | $ | 234.6 | $ | 10.0 | $ | 244.6 | ||||||
| SG&A as a percentage of revenue, as reported | 52.1 | % | 12.7 | % | 45.9 | % | 49.3 | % | 11.5 | % | 43.0 | % | ||||||
| SG&A as a percentage of revenue, as adjusted | 44.8 | % | 11.0 | % | 39.5 | % | 46.7 | % | 10.0 | % | 40.6 | % |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions)
| EBITDA | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, 2023 | Three Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| Net (loss) income | $ | (8.8) | $ | 5.1 | $ | (3.7) | $ | 11.0 | $ | 4.7 | $ | 15.7 |
| Interest expense, net | 3.8 | — | 3.8 | 2.7 | — | 2.7 | ||||||
| Income tax benefit (provision) | 6.2 | 1.6 | 7.8 | (0.9) | 1.2 | 0.3 | ||||||
| Depreciation | 4.8 | — | 4.8 | 4.5 | 1.0 | 5.5 | ||||||
| Amortization | 6.2 | — | 6.2 | 5.5 | 0.6 | 6.1 | ||||||
| EBITDA | 12.2 | 6.7 | 18.9 | 22.8 | 7.5 | 30.3 | ||||||
| Acquisition and integration-related charges | 0.6 | — | 0.6 | 0.2 | — | 0.2 | ||||||
| Restructuring and transformation charges | 4.3 | — | 4.3 | — | — | — | ||||||
| Divestiture related charges | 1.4 | 0.8 | 2.2 | — | — | — | ||||||
| EU MDR Compliance | 0.8 | — | 0.8 | 2.2 | — | 2.2 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Adjusted EBITDA | $ | 27.8 | $ | 7.5 | $ | 35.3 | $ | 25.2 | $ | 7.5 | $ | 32.7 |
| EBITDA | ||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Nine Months Ended September 30, 2023 | Nine Months Ended September 30, 2022 | |||||||||||
| Continuing<br>Operations | Discontinued<br>Operations | Total | Continuing<br>Operations | Discontinued<br>Operations | Total | |||||||
| Net (loss) income | $ | (20.9) | $ | (51.4) | $ | (72.3) | $ | 11.8 | $ | 21.8 | $ | 33.6 |
| Interest expense, net | 9.8 | — | 9.8 | 6.5 | — | 6.5 | ||||||
| Income tax benefit (provision) | 4.1 | 2.2 | 6.3 | 0.6 | 7.1 | 7.7 | ||||||
| Depreciation | 14.2 | 1.8 | 16.0 | 13.3 | 3.0 | 16.3 | ||||||
| Amortization | 17.8 | 0.8 | 18.6 | 16.4 | 1.6 | 18.0 | ||||||
| EBITDA | 25.0 | (46.6) | (21.6) | 48.6 | 33.5 | 82.1 | ||||||
| Acquisition and integration-related charges | 2.4 | — | 2.4 | 3.0 | — | 3.0 | ||||||
| Restructuring and transformation charges | 23.0 | — | 23.0 | — | — | — | ||||||
| Divestiture related charges | 5.1 | 0.8 | 5.9 | — | — | — | ||||||
| Estimated loss on divestiture | — | 72.3 | 72.3 | — | — | — | ||||||
| EU MDR Compliance | 2.8 | — | 2.8 | 5.4 | — | 5.4 | ||||||
| Litigation and legal | 8.5 | — | 8.5 | — | — | — | ||||||
| Adjusted EBITDA | $ | 66.8 | $ | 26.5 | $ | 93.3 | $ | 57.0 | $ | 33.5 | $ | 90.5 |
AVANOS MEDICAL, INC.
NON-GAAP RECONCILIATIONS
(unaudited)
(in millions except per share amounts)
| Free Cash Flow | ||||||||
|---|---|---|---|---|---|---|---|---|
| Three Months Ended September 30, | Nine Months Ended September 30, 2023 | |||||||
| 2023 | 2022 | 2023 | 2022 | |||||
| Cash provided by operating activities | $ | 29.1 | $ | 28.4 | $ | 19.7 | $ | 57.2 |
| Capital expenditures | (3.9) | (5.3) | (11.9) | (14.4) | ||||
| Free Cash Flow | $ | 25.2 | $ | 23.1 | $ | 7.8 | $ | 42.8 |
2023 OUTLOOK
| Estimated Range | |||||
|---|---|---|---|---|---|
| Diluted (loss) earnings per share (GAAP) | $ | (0.22) | to | $ | 0.08 |
| Intangibles amortization | 0.38 | to | 0.34 | ||
| Restructuring and transformation charges | 0.51 | to | 0.42 | ||
| EU MDR compliance | 0.06 | to | 0.05 | ||
| Divestiture related charges | 0.11 | to | 0.09 | ||
| Other | 0.21 | to | 0.17 | ||
| Adjusted diluted earnings per share (non-GAAP) | $ | 1.05 | to | $ | 1.15 |
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions)
| September 30,<br>2023 | December 31,<br>2022 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current Assets | ||||
| Cash and cash equivalents | $ | 107.1 | $ | 127.7 |
| Accounts receivable, net | 145.2 | 167.9 | ||
| Inventories | 156.6 | 132.3 | ||
| Prepaid and other current assets | 13.6 | 13.9 | ||
| Assets held for sale | 102.1 | 58.0 | ||
| Total Current Assets | 524.6 | 499.8 | ||
| Property, Plant and Equipment, net | 116.8 | 118.6 | ||
| Operating Lease Right-of-Use Assets | 27.1 | 27.5 | ||
| Goodwill | 791.5 | 760.3 | ||
| Other Intangible Assets, net | 242.2 | 234.2 | ||
| Deferred Tax Assets | 4.3 | 4.6 | ||
| Other Assets | 18.4 | 17.6 | ||
| Assets Held for Sale | — | 124.3 | ||
| TOTAL ASSETS | $ | 1,724.9 | $ | 1,786.9 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current Liabilities | ||||
| Current portion of long-term debt | $ | 6.2 | $ | 6.2 |
| Current portion of operating lease liabilities | 12.7 | 12.0 | ||
| Trade accounts payable | 52.1 | 67.9 | ||
| Accrued expenses | 97.2 | 98.9 | ||
| Liabilities held for sale | 2.5 | 0.8 | ||
| Total Current Liabilities | 170.7 | 185.8 | ||
| Long-Term Debt | 258.3 | 226.3 | ||
| Operating Lease Liabilities | 29.5 | 32.5 | ||
| Deferred Tax Liabilities | 28.7 | 25.4 | ||
| Other Long-Term Liabilities | 15.6 | 23.5 | ||
| Liabilities Held for Sale | — | 2.2 | ||
| TOTAL LIABILITIES | 502.8 | 495.7 | ||
| Stockholders’ Equity | 1,222.1 | 1,291.2 | ||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 1,724.9 | $ | 1,786.9 |
AVANOS MEDICAL, INC.
CONDENSED CONSOLIDATED CASH FLOW STATEMENTS
(unaudited)
(in millions)
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2023 | 2022 | 2023 | 2022 | |||||
| Operating Activities | ||||||||
| Net (loss) income | $ | (3.7) | $ | 15.7 | $ | (72.3) | $ | 33.6 |
| Depreciation and amortization | 11.0 | 11.6 | 34.6 | 34.3 | ||||
| Loss on asset dispositions | 1.1 | — | 1.1 | — | ||||
| Goodwill impairment | — | — | 59.1 | — | ||||
| Changes in operating assets and liabilities, net of acquisition | 20.6 | (3.4) | (12.1) | (22.7) | ||||
| Deferred income taxes and other | 0.1 | 4.5 | 9.3 | 12.0 | ||||
| Cash Provided by Operating Activities | 29.1 | 28.4 | 19.7 | 57.2 | ||||
| Investing Activities | ||||||||
| Capital expenditures | (3.9) | (5.3) | (11.9) | (14.4) | ||||
| Acquisition of assets and investments in businesses | (45.0) | 0.6 | (47.5) | (116.1) | ||||
| Cash Used in Investing Activities | (48.9) | (4.7) | (59.4) | (130.5) | ||||
| Financing Activities | ||||||||
| Proceeds from issuance of secured debt | — | — | — | 250.0 | ||||
| Secured debt repayments | — | — | (3.1) | (125.0) | ||||
| Revolving credit facility proceeds | 55.0 | — | 55.0 | 150.0 | ||||
| Revolving credit facility repayments | — | — | (20.0) | (150.0) | ||||
| Payments of debt issuance costs | — | — | — | (2.9) | ||||
| Purchase of treasury stock | (9.2) | (11.0) | (12.9) | (45.1) | ||||
| Proceeds from the exercise of stock options | 0.9 | 0.8 | 1.5 | 1.6 | ||||
| Cash Provided by (Used in) Financing Activities | 46.7 | (10.2) | 20.5 | 78.6 | ||||
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (1.6) | (3.0) | (1.4) | (6.8) | ||||
| Decrease in Cash and Cash Equivalents | 25.3 | 10.5 | (20.6) | (1.5) | ||||
| Cash and Cash Equivalents - Beginning of Period | 81.8 | 106.5 | 127.7 | 118.5 | ||||
| Cash and Cash Equivalents - End of Period | $ | 107.1 | $ | 117.0 | $ | 107.1 | $ | 117.0 |
AVANOS MEDICAL, INC.
SELECTED BUSINESS AND PRODUCTS DATA
(unaudited)
(in millions)
| Three Months Ended September 30, | Nine Months Ended<br>September 30, | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | 2022 | Change | 2023 | 2022 | Change | ||||||||||
| Digestive Health | $ | 95.0 | $ | 85.9 | 10.6 | % | $ | 276.8 | $ | 247.5 | 11.8 | % | |||
| Pain Management and Recovery: | |||||||||||||||
| Surgical pain and recovery | $ | 34.1 | $ | 38.9 | (12.3) | % | $ | 103.6 | $ | 118.8 | (12.8) | % | |||
| Interventional pain | 42.2 | 47.5 | (11.2) | % | 119.6 | 136.2 | (12.2) | % | |||||||
| Total Pain Management and Recovery | 76.3 | 86.4 | (11.7) | % | 223.2 | 255.0 | (12.5) | % | |||||||
| Total Net Sales | $ | 171.3 | $ | 172.3 | (0.6) | % | $ | 500.0 | $ | 502.5 | (0.5) | % | |||
| Total | Volume | Pricing/Mix | Currency | Other | |||||||||||
| Net sales - percentage change | QTD | (0.6) | % | (0.9) | % | 0.2 | % | 0.2 | % | (0.1) | % | ||||
| Net sales - percentage change | YTD | (0.5) | % | (0.8) | % | 0.7 | % | (0.4) | % | — | % |